USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Eli Lilly and Novo Nordisk Lead the Obesity Treatment Market

The Motley Fool +1 · ·by G4L

NVO Novo Nordisk ADR
$41.63 +2.41%
View chart & analysis →
  1. 1Eli Lilly recorded a 39% year-over-year revenue growth rate in the third quarter.
  2. 2Eli Lilly achieved $24.4 billion in revenue in the third quarter.
  3. 3Novo Nordisk's net sales grew 6% year-over-year in the third quarter.

So what's the key point?

Eli Lilly's revenue increased significantly by 39% compared to last year. Both companies leading the obesity treatment market earned more money.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →